{'fraction_non_alphanumeric': 0.03140096618357488, 'fraction_numerical': 0.024154589371980676, 'mean_word_length': 5.32824427480916, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma

Liver cancer is a major health problem, being the second leading cause of cancer-related death worldwide, with an annual incidence of more than 850,000 new cases globally. Hepatocellular carcinoma (HCC) represents 85% to 90% of all primary liver cancers and occurs mainly in the setting of chronic inflammatory liver diseases. Only 40% to 50% of patients with HCC are diagnosed at early stages (Barcelona Clinic Liver Cancer [BCLC] 0-A) amenable to potentially curative approaches. However, up to 70% of patients present with disease recurrence within 5 years, and no adjuvant therapies to prevent this complication are available to date. Patients diagnosed at an intermediate stage (BCLC B) are treated with transarterial chemoembolization, whereas 40%